arrow
S

Sani H. Kizilbash

Mayo Clinic
H指数:19
被引数:2,098

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Functional precision genomics identifies transcriptional features of therapeutic response and drug resistance in high-grade gliomas

功能精准基因组学鉴定了治疗反应和药物耐药性在高级别胶质瘤中的转录特征

2026-10-270
OAAI
Early experience with cerebrospinal fluid cell-free DNA molecular profiling in a neuro-oncology practice

神经肿瘤学实践中脑脊液游离DNA分子分型的初步经验

2026-10-030
OA
Protocol for Neuro-Oncology Anywhere: Deploying Mayo Clinic's remote cognitive assessment battery and wearable device monitoring platform while assessing the impact of metformin on cognition and quality of life in patients with history of cranial radiation

神经肿瘤学远程认知评估方案:部署梅奥诊所的远程认知评估测试套件和可穿戴设备监测平台,同时评估二甲双胍对有颅脑放射治疗史患者认知功能和生命质量的影响

2026-05-010
OAAI
Ivosidenib in predominantly recurrent IDH1-mutant glioma: A single-institution experience

ivosidenib在主要复发性IDH1突变型胶质瘤中的应用:一项单机构经验

2026-05-010
PRE
Comparison of clinical, radiographic and genomic alterations between histologic and molecular glioblastoma, IDH-wildtype

IDH野生型星形细胞瘤的病理学诊断与分子分型在临床、影像学及基因组学改变方面的比较

2026-01-010
OA
Predicting Remaining Survival of Glioblastoma Patients with Radiomics Analysis Based on 18F-DOPA PET Images

基于18F-DOPA PET图像的放射组学分析预测胶质母细胞瘤患者的剩余生存期

2025-11-030
OAAI
Pembrolizumab efficacy in recurrent adult-type diffuse gliomas

帕博利珠单抗在复发成人型弥漫性胶质瘤中的疗效

2025-11-010
OAAI
UPDATED RESULTS OF PHASE 3 STELLAR TRIAL: EFLORNITHINE IMPROVES OVERALL SURVIVAL AND BLINDED INDEPENDENT CENTRAL REVIEW DETERMINED PROGRESSION FREE SURVIVAL IN PATIENTS WITH RECURRENT WHO 2021 GRADE 3 IDH-MUTANT ASTROCYTOMA

更新后的III期STELLAR试验结果:依氟鸟氨酸改善2021年WHO分级3级IDH突变型星形细胞瘤患者的总生存期和盲态独立中央审查确定的无进展生存期

2025-11-010
OAAI
Multivariate survival risk stratification in GBMs lacking necrosis and microvascular proliferation

胶质母细胞瘤中缺乏坏死和微血管增生的多变量生存风险分层

2025-11-010
OAAI
Neuro-oncology anywhere (NOA) 242: Interim results from a pragmatic clinical trial evaluating telehealth versus in-person evaluations for individuals with glioma undergoing oral chemotherapy

神经肿瘤学无处不在(NOA)242:一项实用型临床试验的初步结果,评估远程医疗与面对面评估对于接受口服化疗的胶质瘤患者的影响

2025-11-010
OAAI
Clinical utility of RANO 2.0 for response assessment to immunotherapy in recurrent gliomas

RANO 2.0在复发性胶质瘤免疫治疗反应评估中的临床应用价值

2025-11-010
PRE
Neuro-oncology anywhere: A fully decentralized clinical trial evaluating cognitive assessments and interventions for patients who received intracranial radiation therapy

神经肿瘤学无处不在:一项完全去中心化的临床试验,评估接受颅内放射治疗患者的认知评估和干预措施

2025-11-010
OAAI
WSD0922-FU THERAPY IN PATIENTS WITH EGFR MUTANT GLIOBLASTOMA - UPDATES FROM THE DOSE EXPANSION COHORTS OF A FIRST-IN-HUMAN PHASE 1 CLINICAL TRIAL (MC1914)

WSD0922-FU疗法在EGFR突变型胶质母细胞瘤患者中的应用——来自一项首次人体I期临床试验(MC1914)剂量扩展队列的更新信息

2025-11-010
OAAI
Comparison of clinical, radiographic and genomic alterations between classic and molecular glioblastoma, IDH-wildtype (updated report)

比较经典型与分子型胶质母细胞瘤(IDH野生型)的临床、影像学和基因组改变(更新报告)

2025-11-010
OAAI
RELATIONSHIPS BETWEEN LYMPHOCYTE COUNTS AND CLINICAL OUTCOMES IN PATIENTS WITH GLIOMAS TREATED WITH PEMBROLIZUMAB

胶质瘤患者接受帕博利珠单抗治疗后淋巴细胞计数与临床结局的关系

2025-11-010
OAAI